Roches Alecensa alectinib significantly reduced the risk of disease worsening or death as a firstline treatment in Asian patients with ALKpositive advanced or metastatic nonsmall cell lung cancer

Roche’s Alecensa (alectinib) significantly reduced the risk of disease worsening or death as a first-line treatment in Asian patients with ALK-positive advanced or metastatic non-small cell lung cancer

Roche will today announce results from the phase III ALESIA study, showing that Alecensa® (alectinib) met its primary endpoint of investigator-assessed (INV) progression-free survival (PFS).

More From BioPortfolio on "Roche’s Alecensa (alectinib) significantly reduced the risk of disease worsening or death as a first-line treatment in Asian patients with ALK-positive advanced or metastatic non-small cell lung cancer"